Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba’s technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn’s disease, asthma/COPD and acute lung injury.

March 17, 2009 - Alba Therapeutics Corporation Announces the Next Clinical Trial of its Lead Compound, Larazotide Acetate and Promotions

November 11, 2008 - Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease

October 7, 2008 - Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting